These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827 [TBL] [Abstract][Full Text] [Related]
10. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings. Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. Hall S; Janelidze S; Surova Y; Widner H; Zetterberg H; Hansson O Sci Rep; 2018 Sep; 8(1):13276. PubMed ID: 30185816 [TBL] [Abstract][Full Text] [Related]
13. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Shi M; Bradner J; Hancock AM; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Kim HM; Leverenz JB; Montine TJ; Ginghina C; Kang UJ; Cain KC; Wang Y; Aasly J; Goldstein D; Zhang J Ann Neurol; 2011 Mar; 69(3):570-80. PubMed ID: 21400565 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Holmberg B; Johnels B; Blennow K; Rosengren L Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213 [TBL] [Abstract][Full Text] [Related]
16. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895 [TBL] [Abstract][Full Text] [Related]
17. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases. Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206 [TBL] [Abstract][Full Text] [Related]
19. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721 [TBL] [Abstract][Full Text] [Related]
20. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM; JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]